Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $51.68 and last traded at $50.60, with a volume of 35950 shares traded. The stock had previously closed at $48.17.
A number of equities analysts recently commented on the company. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. Chardan Capital increased their price objective on Arrowhead Pharmaceuticals from $32.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. ValuEngine downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Piper Jaffray Companies increased their price objective on Arrowhead Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Sunday, October 20th. Finally, Robert W. Baird downgraded Arrowhead Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a report on Thursday, October 24th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $49.40.
The stock has a market cap of $4.50 billion, a P/E ratio of -78.34 and a beta of 1.68. The business has a 50-day simple moving average of $37.43 and a 200-day simple moving average of $29.71.
Several institutional investors and hedge funds have recently bought and sold shares of ARWR. Arlington Capital Management Inc. bought a new position in Arrowhead Pharmaceuticals in the third quarter worth $823,000. Mason Street Advisors LLC increased its position in Arrowhead Pharmaceuticals by 2.2% in the third quarter. Mason Street Advisors LLC now owns 32,360 shares of the biotechnology company’s stock worth $912,000 after purchasing an additional 711 shares during the period. Tower Research Capital LLC TRC increased its position in Arrowhead Pharmaceuticals by 2,008.0% in the third quarter. Tower Research Capital LLC TRC now owns 8,453 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 8,052 shares during the period. Alps Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals in the third quarter worth about $348,000. Finally, SG Americas Securities LLC increased its position in Arrowhead Pharmaceuticals by 239.1% in the third quarter. SG Americas Securities LLC now owns 83,005 shares of the biotechnology company’s stock worth $2,339,000 after purchasing an additional 58,527 shares during the period. 72.30% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.